IAP

HMS Core: Create Outstanding Apps and Elevate User Experience

Retrieved on: 
Monday, November 14, 2022
IAP, Air travel, SDK, Open, Huawei Mobile Services, AI, York Publishing Services, Travel, Growth, Smart device, Ecosystem, Machine learning, Solution, Huawei, Security, News, Dubai World Trade Centre, HMS, IOS SDK, Mobile phone, Video game, Satellite navigation device

This toolset helps developers create apps quickly with the aim of achieving rapid growth and business monetization.

Key Points: 
  • This toolset helps developers create apps quickly with the aim of achieving rapid growth and business monetization.
  • HMS Core not only offers practical functions that can easily be integrated, but also helps developers scale and monetize their apps.
  • In the Apps Services field, HMS Core Push Kit enables developers to send messages and data to their apps on user devices.
  • As the showpiece of the event, HMS Core will continue opening powerful capabilities to help developers create fun, user-friendly apps.

Theriva Biologics Reports Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 10, 2022
NYSE American, HCT, Research, Sale, Public relations, CGMP, Company, GMP, Degenerative disease, Form 8-K, Review, IV, Marketing, NYSE, IAP, Telephone, Incidence, VCN, SEC, Time, Cancer, Orphan drug, Patient, Neck, Acquisition, Private Securities Litigation Reform Act, PDAC, SIOP, Brain, Neoplasm, VRE, DSMC, AEMPS, Clinical trial, Maintenance, Terminology, Growth, Retinoblastoma, Congress, FDA, Trial of the century, Income, GLOBE, University, Head, ESMO, International Society, Durvalumab, Data, Safety, Hospital Sant Joan de Déu Barcelona, Therapy, Insurance, Vancomycin, Mobile phone, Pharmaceutical industry, American

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported financial results for the quarter ended September 30, 2022, and provided a corporate update.
  • We are encouraged by our clinical results demonstrating the therapeutic potential of Therivas oncology-focused platform, said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics.
  • In October 2022, the Company rebranded as Theriva Biologics and began trading on NYSE American under the new ticker symbol TOVX.
  • ET to review the third quarter 2022 operational highlights and financial results.

Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 10, 2022
GLOBE, IV, NYSE, IAP, HCT, Telephone, Neoplasm, Incidence, VRE, VCN, CGMP, Cancer, Degenerative disease, Therapy, Vancomycin, Pharmaceutical industry

ROCKVILLE, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that it plans to host a conference call on Friday, November 11, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update. The call was originally scheduled for Thursday, November 10, 2022, at 8:30 a.m. ET.

Key Points: 
  • ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.
  • The call was originally scheduled for Thursday, November 10, 2022, at 8:30 a.m.
  • Individuals may participate in the live call via telephone by dialing 1-888-254-3590 (domestic) or 1-929-477-0402 (international) and using the conference ID: 5687287.
  • Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.

Lawful Interception Global Market Opportunities And Strategies To 2031

Retrieved on: 
Tuesday, November 8, 2022
Benchmark, Cisco Systems, Inc., Geography, Microsoft Content Management Server, Coronavirus, Landscape, Industry, IAP, Abbreviation, BAE Systems, COVID-19, GDP, Communication, Appendix, NAICS, Demography, Create, Research, Analysis, Statistical conclusion validity, Sun Records (other companies), Animal, Retail, Marketing, Sales, Gateways, Growth, Ericsson

NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Lawful Interception Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global lawful interception market as it emerges from the COVID-19 shut down.

Key Points: 
  • NEW YORK, Nov. 8, 2022 /PRNewswire/ -- Lawful Interception Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global lawful interception market as it emerges from the COVID-19 shut down.
  • It places the market within the context of the wider lawful interception system market; and compares it with other markets.
  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, defintions and explanations about the lawful interception market.
  • Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.

Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Retrieved on: 
Thursday, November 3, 2022
Patient, VRE, Piperacillin/tazobactam, Infection, Neoplasm, Private Securities Litigation Reform Act, Washington University School of Medicine, Form 8-K, Therapy, Growth, Time, Maintenance, Washington University in St. Louis, Cohort, IV, CGMP, CDI, Sale, GLOBE, Meropenem, Vancomycin, Clostridioides difficile infection, Clostridioides, Washington University School of Law, NYSE, Safety, Incidence, Terminology, Marketing, Subclinical infection, Degenerative disease, HCT, Annual report, Cefepime, Hematological Cancer Research Investment and Education Act, Clinical trial, Fever, GI, Risk, VCN, Absorption, IAP, SEC, Cancer, Pharmaceutical industry

ROCKVILLE, Md., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the first patient has been dosed in Cohort 2 of its Phase 1b/2a randomized, double-blinded, placebo-controlled clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD).

Key Points: 
  • The ongoing randomized, double-blinded, placebo-controlled Phase 1b/2a clinical trial is being conducted at Washington University School of Medicine in St. Louis.
  • The trial is designed to evaluate the safety, tolerability, and potential absorption of oral SYN-004 (150 mg q.i.d.
  • for a maximum of 28 days) into the systemic circulation of allogeneic HCT recipients who receive an IV antibiotic to treat fever.
  • Patients in Cohorts 2 and 3 will be administered piperacillin/tazobactam and cefepime respectively, each of which can be metabolized by SYN-004.

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results

Retrieved on: 
Thursday, November 3, 2022
VRE, Neoplasm, Telephone, Therapy, IV, CGMP, GLOBE, Vancomycin, NYSE, Incidence, Degenerative disease, HCT, VCN, IAP, Cancer, Pharmaceutical industry

ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.

Key Points: 
  • ET to discuss its financial results for the quarter ended September 30, 2022 and provide a corporate update.
  • Individuals may participate in the live call via telephone by dialing 1-888-254-3590 (domestic) or 1-929-477-0402 (international) and using the conference ID: 5687287.
  • Participants are asked to dial in 15 minutes before the start of the call to register.
  • Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.

Theriva Biologics to Host Key Opinion Leader Webinar on Lead Program, VCN-01 and Advancing Unique Oncolytic Virus Therapeutics

Retrieved on: 
Monday, October 31, 2022
HCT, Vancomycin, Cancer, Research, Duke University School of Medicine, Patient, IV, VCN, KOL, Degenerative disease, NYSE, VRE, PDAC, CGMP, Company, Q&A, GLOBE, Oncology, Department, Pancreatic cancer, IAP, Gastrointestinal disease, Neoplasm, Incidence, Breast, Therapy, Melanoma, Pharmaceutical industry, Medicine

The discussion will also include recent findings from independent research highlighting the market opportunities for pancreatic ductal adenocarcinoma (PDAC).

Key Points: 
  • The discussion will also include recent findings from independent research highlighting the market opportunities for pancreatic ductal adenocarcinoma (PDAC).
  • VCN-01, Theriva Biologics lead clinical-stage drug candidate, is an intravenous, oncolytic adenovirus designed to break down the tumor stroma.
  • Therivas upcoming Phase 2 clinical trial, VIRAGE, will evaluate VCN-01 in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel in patients with PDAC.
  • Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.

Theriva Biologics Announces Presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference Describing Phase 1 Investigator-sponsored Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cel

Retrieved on: 
Monday, October 24, 2022
Therapy, Durvalumab, HCT, Head, Conference, Neoplasm, Neck, CGMP, VRE, NYSE, Patient, IV, Degenerative disease, VCN, Cancer, Company, Incidence, GLOBE, IAP, Pharmaceutical industry

Data will be featured in an oral presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference, being held from in Karuizawa, Japan from October 23-26.

Key Points: 
  • Data will be featured in an oral presentation at the 14th International Oncolytic Virotherapy (IVOC) Conference, being held from in Karuizawa, Japan from October 23-26.
  • A copy of the presentation will be accessible under the Events section of the Theriva Biologics website.
  • Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need.
  • The Company was formed through the merger of Synthetic Biologics Inc. and VCN Biosciences, S.L.

Google Ads and Meta Ads continues to dominate remarketing index despite Apple's privacy changes: AppsFlyer Performance Index 15

Retrieved on: 
Tuesday, October 18, 2022
Google Marketing Platform, Apple, Observation, Risk, Efficiency, Meta, ATT, Android, Privacy, Google, Singapore, Technology, AppLovin, Budget, AppsFlyer, Partner development, Ecosystem, IOS, IAP, Video game, Satellite navigation device, Mobile phone, Online shopping, SKAN, Overalls, Industry, App

Notably, both Google Ads and Meta Ads have lost ground on iOS due to Apple's privacy changes.

Key Points: 
  • Notably, both Google Ads and Meta Ads have lost ground on iOS due to Apple's privacy changes.
  • However on the Android market, Google Ads and Meta Ads continues to maintain its domination throughout Southeast Asia thanks to its unrivaled scale.
  • A deeper dive into these rankings indicates a major loss in app install market shares for Google Ads and Meta Ads in H1.
  • Google Ads and Meta Ads have maintained their lead in the top two positions, while Google Marketing Platform shows rapid growth moving to 3rd position.

AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting

Retrieved on: 
Thursday, October 20, 2022
CDE, Merck, Therapy, Mayo Clinic, Institute, Treatment, American Association, Association, Congress, The Pauly D Project, Priority review, BTD, California Department of Alcohol and Drug Programs, Cancer, NMPA, Infection, CHB, Motherboard, Degenerative disease, Hepatology, Odds, FDA, Biotechnology, RPD, AstraZeneca, FTD, DC, National Medical Products Administration, Hepatitis, Multimedia, TKI, Jingxi Nanfang Hospital station, Apoptosis, AASLD, IAP, Unity Biotechnology, Southern Medical University, Patient, Stock exchange, Center for Drug Evaluation and Research, ODD, CML, MD Anderson Cancer Center, Institute of Liver and Biliary Sciences, Center, Dana–Farber Cancer Institute, Pharmaceutical industry, Vaccine, Fine chemical, Pfizer, EU

The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.

Key Points: 
  • The AASLD Annual Meeting is one of the most anticipated scientific gatherings in the field of hepatology.
  • This year's congress will take place both online and in-person in Washington, DC, the United States, during November 4th to 8th, 2022.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.